Have you or your loved ones been diagnosed with metastatic neuroendocrine tumor?

You may be eligible to participate in a metastatic neuroendocrine tumor clinical trial.

Have you or your loved ones been diagnosed with metastatic neuroendocrine tumor? You may be eligible to participate in a metastatic neuroendocrine tumor clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Neuroendocrine Tumors
NCT03034200 | Phase 2 | Interventional
Peter Anderson
Sponsored by
Peter Anderson

Have you or your loved ones been diagnosed with metastatic neuroendocrine tumor?

You may be eligible to participate in a metastatic neuroendocrine tumor clinical trial.

Have you or your loved ones been diagnosed with metastatic neuroendocrine tumor? You may be eligible to participate in a metastatic neuroendocrine tumor clinical trial.

Completed

Male & Female

14 Years +

This study has recruited 30 Participants

The purpose of this study is to learn if a new drug, ONC201 can make tumors become smaller or go away completely. Investigators also want to learn if ONC201 can prevent new deposits of cancer from appearing in new places in participants (metastases). A phase 2 study of ONC201 in PC-PG (pheochromocytoma-paraganglioma) and other neuroendocrine tumors will determine whether inhibition of DRD2 (a member of the dopamine receptor family) is safe in unresectable, recurrent, locally advanced, refractory, or metastatic neuroendocrine cancers including PC-PG, desmoplastic small round cell tumor (DSRCT), Ewing sarcoma (PNET) or any other neuroendicrine tumor with a catecholamine or dopamine biomarker or autocrine or paracrine dependence on dopamine including cholangiocarcinoma and adrenal cortical carcinoma. ONC201 is an investigational (experimental) agent and has a favorable safety profile in phase 1 and early phase 2 clinical trials in advanced cancers. This study design has been chosen to see whether ONC201 is associated with reduction of anti-hypertension medications, safety and significant efficacy against neuroendocrine tumors, especially PC-PG.